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Abstract 
Background: Beyond their role in haemostasis and thrombosis, platelets are also important 
mediators of inflammation by the release of hundreds of factors stored in their α-granules. 
Mutations in Nbeal2 cause gray platelet syndrome (GPS) characterized by the lack of platelet 
α-granules. This study aims to evaluate the immunological (pro-inflammatory) effects of 
platelet α-granules. 
Methods and Materials: We performed experiment using Nbeal2-/- mice, the mouse model 
of GPS. Systemic inflammation was induced by intravenous injection of lipopolysaccharide 
(LPS). Inflammatory response was assessed by quantification of inflammatory soluble factors 
and platelet biological response modifiers. 
Results: The lack of Nbeal2 (in Nbeal2-/- mice, compared to controls) significantly reduced 
the recruitment of circulating neutrophils and monocytes. Moreover, after LPS injection, 
there was a significant increase in neutrophil and monocyte counts in control animals, 
compared to Nbeal2-/- mice. The control of inflammation, evaluated by the production of 
anti-inflammatory cytokines, appeared to be greater in Nbeal2-/- mice compared with 
controls. Conversely, the production of certain inflammatory-soluble mediators known to 
characterize normal platelet secretion, such as sCD40L, was decreased under experimental 
inflammation in Nbeal2-/- mice.  
Conclusions: These results show that α-granules play a direct role in platelet-mediated 
inflammation balance, confirming the need to further investigate platelet-associated 
inflammatory pathophysiology and inflammatory adverse events related to blood 
transfusion. 
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Introduction 
Platelets are enucleated secretory cells that circulate in blood and are mostly characterized 
by their role in haemostasis and thrombosis.1 However, platelets have also been recognized 
as mediators of inflammation and immunity.2 Platelets and their progenitors, 
megakaryocytes (MKs), express surface receptors that can initiate/propagate inflammatory 
responses such as "Toll-like" receptor- 4 (TLR-4), TLR-2 and TLR-9,3 sialic acid-binding 
immunoglobulin-type lectin (Siglec) receptors and specifically Siglec-7,4 and numerous 
cytokine and chemokine receptors that are essential in cell migration and communication.5 
Therefore, the role of platelets in inflammation is not limited to the expression of the 
multiple aforementioned receptors that primarily sense pathogens, relying also on 
inflammatory soluble factors stored in the α-granules and released upon secretion,6 such as 
CD62P, CD40L, platelet factor 4 (PF4), MIP-1α, RANTES and IL-1. The majority of soluble 
factors stored in α-granules are proinflammatory,7 however, many studies also suggest 
platelets have an anti-inflammatory role. Indeed, higher levels of tumor necrosis factor-α 
(TNF-α), IL-6 and interferon-γ (IFN-γ) have been observed in sera and plasma in the absence 
of platelets.8,9 Moreover, the transfusion inflammatory reaction in the vascular 
compartment involves endothelial cell activation due to cell-cell interactions and 
inflammatory soluble factors infused with the blood products. Furthermore, platelets can 
regulate the inflammatory response of blood neutrophils by influencing the expression of 
macrophage receptor-1 (Mac-1) on their surface, notably through platelet integrin GPIb-IX 
exposure.9 The balance between the pro- and anti-inflammatory factors stored in the α-
granules and the platelet response through the TLR and chemokine receptors should thus 
determine the overall role of platelets in inflammation. 
Gray platelet syndrome (GPS) is a rare platelet bleeding disorder caused by loss of function 
mutations in NBEAL2 and characterized by a low platelet count, a lack of platelet α-granules 
and early myelofibrosis. Deletion of its murine ortholog, Nbeal2, recapitulates all major 
features of GPS. Mouse Nbeal2-/- platelets have a significant decrease, or an almost 
complete absence, in α-granule proteins such as PF4, vWF and P-selectin 10-13 with a 
potential imbalance of inflammation. In fact, Nbeal2-/- mice are more vulnerable to bacterial 
(Staphylococcus aureus) and viral (murine cytomegalovirus) infection.14 The objective was 
therefore to investigate the effect of platelet α-granule content on the amplification or 
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down-regulation of LPS-induced systemic inflammation in Nbeal2-/- mice, to reveal the pro- 
and anti-inflammatory balance. 
Material and methods 
Mice 
Adult, male, C57BL6 mice between 8 and 13 weeks old were used. For each experiment, a 
minimum of 6 mice were used. The mice were randomly distributed into different groups 
(PBS wild type [WT] vs. LPS WT vs. PBS Nbeal2-/- vs. LPS Nbeal2-/-). This research was 
performed under the Animals (Scientific Procedures) Act 1986 Amendment Regulations 
2012, following an ethical review by the University of Cambridge Animal Welfare and Ethical 
Review Body (AWERB). 
LPS Challenge 
Mice were intravenously (i.v.) injected with LPS extracted from Escherichia coli (0111) (Sigma 
Aldrich, Saint-Louis, USA) used at 10 mg/kg, or with PBS (control). Mice were monitored for 
5 hours. The surviving mice were then euthanized in a carbon dioxide chamber and blood 
was collected in acid citrate-dextrose (ACD) (Sigma Aldrich, Saint-Louis, USA).  
Cell Counting 
Blood was collected in ACD solution. Full blood counts were measured using a “scil Vet abc” 
instrument (scil Vet abc, Montpellier, France). Plasma was obtained by centrifugation and 
frozen at -80°C until used.  
Inflammatory Soluble Factors and Platelet Biological Response Modifiers Immunoassay 
The mouse biological response modifier (BRM) magnetic 16-plex kit (IL-1β, bFGF, IL-10, IL-13, 
IL-6, IL-12, IL-17, GM-CSF, IL-5, IL-1α, IFN-γ, TNF-α, IL-2, IP-10, MIG and IL-4) (ThermoFisher, 
Waltham, USA), magnetic 5-plex kit (KC, MCP-1, MIP-1α, RANTES and VEGF) and magnetic 
simplex kit (sCD40L) (Merck Millipore, Billerica, USA) were used according to the 
manufacturers’ instructions. The reading was taken through the Luminex 200 (Luminex, 
Austin, USA). 
Statistical Tests 
Statistical analyses were performed using GraphPad Prism 5 software (GraphPad, San Diego, 
USA). P-values were calculated using a 2-tailed unpaired T test, a one-way ANOVA and a 
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Bonferroni post-hoc test when the Kolmogorov-Smirnov normality test was passed. P-values 
were calculated using a 2-tailed Mann-Whitney test, a Kruskal-Wallis test, a one-way ANOVA 
and Dunn’s post-hoc test when the Kolmogorov-Smirnov normality test failed. A p-value was 
considered significant when it was < 0.05 for all tests. Using *, † and # < 0.05; **, †† and ## < 
0.01; ** *, ††† and ### < 0.001 symbols. 
 
Results and Discussion  
Inflammatory Cell Recruitment Changes Dependent upon NBEAL2 Protein Expression  
Firstly, the circulating cell count revealed a significant 3- and 4- fold increase in the 
neutrophil and monocyte counts respectively, in Nbeal2-/- mice compared with control mice. 
The effect of LPS intravenous injection was then assessed demonstrating that LPS injection 
significantly increased the number of monocytes and reduced the number of platelets and 
circulating lymphocytes in both WT and Nbeal2-/- mice. Reciprocally, the number of 
neutrophils significantly increased in WT mice after LPS injection, but not in Nbeal2-/- mice 
(Fig 1, A, B). The fold change of the cell populations before and after LPS injection revealed a 
significant increase in the neutrophil and monocyte counts in control animals compared with 
Nbeal2-/- mice (Fig 1, C). These results show that Nbeal2-/- mice mobilize leukocytes 
(neutrophils and monocytes) less efficiently than WT mice following LPS-induced systemic 
inflammation. A likely explanation for this is that Nbeal2-/- mice have a limited capacity for 
secreting pro-inflammatory mediators capable of synergizing at the systemic level. Indeed, it 
has already been shown that platelets, by the release of a multitude of soluble mediators 
contained in the α-granules, play an essential role in attracting and capturing leukocytes.7 
An Anti-Inflammatory Pattern is Revealed in Nbeal2-/- Mice after LPS Injection 
The purpose was to evaluate the influence of platelet secretion on inflammation evaluated 
through cytokine/chemokine production from inflammatory cells. The concentrations of 15 
cytokines/chemokines were therefore measured with pro- and anti-inflammatory function, 
in WT and Nbeal2-/- mice challenged systematically by LPS. Under the baseline condition (i.e., 
PBS injection), levels of IL-10, an anti-inflammatory BRM,15 were only higher in WT mice 
compared with Nbeal2-/- mice. Systemic LPS injection induced a significant increase in 10 
pro-inflammatory soluble factors in both WT and Nbeal2-/- mice, including IL-6, IL-12, GM-
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CSF, IL-5, IL-1α, IFN-γ, TNF-α, IL-2, IP-10 and MIG. Only the concentration of IL-17 was higher 
in Nbeal2-/- mice than in control mice under the effects of LPS-induced inflammation, but this 
difference was not significant. Higher levels of anti-inflammatory BRMs (IL-10, 15 IL-13, and 
IL-416) were only observed in Nbeal2-/- mice after systemic LPS injection (Table 1), which 
correlated with their fold increase (Fig 2, A). In summary, under systemic inflammatory 
conditions, Nbeal2-/- mice show a more sustained anti-inflammatory response normally 
hidden or limited in WT animals. These results could therefore support the possibility that 
the secretion of platelet α-granule products can change the secretory pattern of 
inflammatory cells and balance pro- and anti-inflammatory BRMs and, overall, inflammation. 
Circulating Blood Cells Compensate for the Decrease in Pro-inflammatory Platelet-released 
factors in Nbeal2-/- Mice, Except for sCD40L. 
Platelets and other blood and vascular cells secrete BRMs such as IL-1β, KC, MCP-1, MIP-1α, 
RANTES, VEGF and sCD40L under physiological conditions and, to a greater degree, upon 
stimulation. While sustained production of IL-1β,17 KC,18 MCP-1,19 MIP-1α,20 RANTES 19 and 
VEGF 21 is a common feature of platelets and other cells, sCD40L is mostly secreted by 
platelets.22 It was therefore investigated whether the lack of platelet secretion, particularly 
for these seven soluble factors, could be compensated by other blood cells in Nbeal2-/- mice. 
Concentrations of IL-1β, KC, MCP-1, MIP-1α, RANTES and VEGF, measured in blood plasma, 
were significantly increased after stimulation induced by LPS injection in both wild type and 
Nbeal2-/- mice (Table 1). These results indicate that other inflammatory blood cells have a 
potential compensatory capacity for secretion. However, sCD40L followed a different 
pattern as observed by a 2.5-fold increase in its levels in PBS-injected Nbeal2-/- mice when 
compared to control animals (Fig 2, A and Table 1). sCD40L follows a pattern previously 
observed with other factors released by platelets, such as PF4 and BTG, which have been 
found at higher levels in plasma of patients with gray platelet syndrome.23 Additionally, 
CD40L expression might be greater in Nbeal2-/- megakaryocytes than in WT cells, as has been 
reported for other pro-inflammatory chemokines.10 We furthermore cannot exclude the 
possibility that the expression of CD40L in cells other than platelets may influence its serum 
levels. The increased concentration of sCD40L may therefore be the consequence of a 
significant expression of certain proteins by the megakaryocytes or a lack of clearance of the 
plasma. Lastly, this raised concentration of sCD40L, evidenced in non-stimulated Nbeal2-/- 
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mice, is likely to partially explain the high baseline count of circulating neutrophils and 
monocytes (Fig 1, A, B). Indeed, CD40L, and its agonist form sCD40L, typically participate in 
leukocyte recruitment notably by binding leukocyte CD40 and Mac-1 receptors 24. Under 
inflammation induced through LPS intravenous injection, sCD40L levels increased in WT mice 
in contrast to Nbeal2-/- mice (Fig 2, B), which seems to correlate with the limitation of 
neutrophil and monocyte recruitment in control (Fig 1, C). The secretion of certain platelet 
BRMs,25 such as sCD62P, vWF, PF4, and fibrinogen, is indeed reduced in Nbeal2-/- mice, 10-13 
which may contribute to the increased concentration of anti-inflammatory factors observed 
in these mice (Fig 2, A). In this study, a comparable pro-inflammatory cytokine/chemokine 
secretion pattern was observed in Nbeal2-gene deficiency and wild type conditions, except 
for sCD40L secretion. Nevertheless, the anti-inflammatory profile was greater when mice 
lacked α-granules and were stimulated with intravenous LPS. 
These observations are consistent with a recent study showing that the lack of NBEAL2 
protein expression in mice increases their vulnerability to bacterial infection.14 Sowerby et 
al. demonstrated that abnormalities exist in the Nbeal2-deficient immune system, especially 
with respect to neutrophil and NK cell function. Our results suggest that other inflammatory 
blood cells may be involved in compensatory secretion. Because the circulating cell count 
indicated non-significant modulation of lymphocyte concentration in Nbeal2-/- mice, in 
comparison with control mice, we hypothesize that activating lymphocytes may exhibit such 
compensatory secretion. We cannot exclude a possible role of nonimmune cells, such as 
endothelial cells, in the release of immunomodulatory factors.26 
Platelets concentrates are known to provide a higher rate of adverse recipients reactions 
than other blood components. Cytokine accumulation during platelets storage may result in 
increased risk of transfusion reactions. Our understanding of the molecular mechanisms of 
secretion and the genetic regulation of granule biogenesis still remains incomplete. In the 
present report, we expand our understanding of how platelets balance of anti- and pro-
inflammatory factors to regulate inflammation. In an elegant approach, Deppermann et al. 
11,12 show that a deficiency in platelet α- and dense granules results in impaired vascular 
integrity in the course of thrombo-inflammatory brain infarction but not in experimental 
inflammation of the skin or lung. This indicates that the mechanisms by which platelets 
maintain vascular integrity differ between inflamed organs. Moreover, these results 
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demonstrate that platelet granule release safeguards hemostasis during stroke injury. 
Platelet-specific mediators released from platelets (especially from α-granules) can 
themselves promote inflammation. Such platelet-specific mediators are able to regulate 
endothelial activation and migration to sites of vascular lesions. Platelets have the potential 
to modulate vascular permeability and integrity. In the context of transfusion, adverse 
reactions depend not only on the blood products but also on patients’ genetic backgrounds 
and underlying pathological conditions. Further investigation is needed to understand the 
extent to which platelet components affect patients and their inflammatory status, and 
future studies using platelet-specific knockouts of α-granule–derived mediators will enhance 
our understanding of the role of platelets in adverse events related to blood transfusion. 
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	 	 PBS WT PBS Nbeal2-/- LPS WT LPS Nbeal2-/- 
p-
value 
symbol 
Pro 
inflammation 
properties 
bFGF 144.29 ± 55.04 90.61 ± 19.93 104.67 ± 19.75 164.71 ± 66.61  
IL-1β 64.86 ± 17.30 62.05 ± 17.42 290.35 ± 40.82 293.78 ± 64.20 * * *  ††† 
IL-6 57.50 ± 20.57 62.66 ± 57.32 41752.00 ± 15259.62 41295.70 ± 19058.35 * * *  † 
IL-12 63.19 ± 8.98 73.74 ± 23.88 742.91 ± 266.31 746.19 ± 437.51 * *  †† 
IL-17 2.62 ± 1.65 1.45 ± 1.10 17.26 ± 12.22 24.39 ± 17.05 * *  
GM-CSF 12.23 ± 5.47 4.90 ± 0.31 81.25 ± 18.74 74.17 ± 18.57 * * *  † 
IL-5 59.02 ± 36.87 12.82 ± 3.37 417.85 ± 71.15 271.65 ± 77.84 *  †† 
IL-1α 1.67 ± 0.38 1.40 ± 0.23 20.60 ± 14.60 19.28 ± 9.30 * * *  † 
IFN-γ 52.46 ± 28.58 22.92 ± 18.98 866.40 ± 496.46 761.59 ± 511.26 * *  † 
TNF-α 15.80 ± 9.77 7.51 ± 5.66 410.75 ± 63.25 403.07 ± 162.51 * * *  † 
IL-2 11.33 ± 2.81 7.06 ± 1.86 35.04 ± 5.67 33.40 ± 4.27 * * *  ††† 
IP-10 39.43 ± 13.98 36.14 ± 6.25 8911.97 ± 2241.85 9673.37 ± 4528.40 
* * *  
††† 
MIG 157.17 ± 30.59 123.60 ± 38.18 101899.66 ± 32534.36 
100400.95 ± 
35539.99 
* * *  
††† 
KC 140.09 ± 78.44 292.41 ± 230.32 12455.28 ± 418.95 13141.09 ± 2113.74 
* *  
†† 
MCP-1 38.39 ± 11.31 70.24 ± 35.87 13718.63 ± 2553.77 18277.49 ± 3738.30 * *  † 
MIP-1α 59.62 ± 38.13 36.32 ± 4.31 1279.17 ± 745.14 1154.02 ± 500.22 
* *  
† 
RANTES 23.42 ± 6.19 52.85 ± 25.47 6961.41 ± 4197.66 9727.42 ± 5734.19 * *  †† 
VEGF 3.60 ± 0.77 3.38 ± 0.73 10.90 ± 3.90 10.36 ± 2.93 
* *  
†† 
sCD40L 138.27 ± 38.84 331.12 ± 108.81 322,14 ± 88,72 293.33 ± 74.19 
† 
# 
Anti-
inflammatory 
properties 
IL-10 351.20 ± 185.54 65.74 ± 24.46 431.90 ± 142.41 490.79 ± 293.82 
* *  
# 
IL-13 61.89 ± 18.39 45.81 ± 13.68 85.07 ± 23.62 91.93 ± 20.80 * *  
IL-4 51.55 ± 21.95 20.21 ± 4.36 75.91 ± 11.47 91.32 ± 29.51 * * *  
 
Table 1: Value Representation of the Soluble Factor Evaluations 
Value quantification for each soluble factor in plasma was determined through a multiplex 
assay for each group of mice. The unit is pg/ml. Data are presented as means ± SEM (n = 6 – 
9). *p < 0.05; **p < 0.01 and ***p < 0.001 represent differences between Nbeal2-/- groups. ; 
†p < 0.05; ††p < 0.01 and †††p < 0.001 represent differences between wild type groups. ; #p 
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< 0.05; ##p < 0.01 and ###p < 0.001 represent differences between PBS groups. One-way 
ANOVA revealed no statistical difference between LPS groups. 
 
Figure legends 
 
Figure 1: Evaluation of Blood Cell Count 
Blood cell counts (A) and Mean platelet volume were evaluated for each group of mice (B). 
The fold increase in numbers of cells after LPS injection for each condition was determined 
(C). Data are presented as means (n = 6–9). *p < 0.05, **p < 0.01, and ***p < 0.001 
represent differences between Nbeal2-/- groups. †p < 0.05, ††p < 0.01, and †††p < 0.001 
represent differences between wild type groups. #p < 0.05, ##p < 0.01, and ###p < 0.001 
represent differences between PBS groups. §p < 0.05, §§p < 0.01, and §§§p < 0.001 
represent differences between LPS groups. 
 
Figure 2: Evaluation of Pro-Inflammatory Pattern for Mouse Soluble Factors and Platelet 
Soluble Factor Assay 
Evaluation of pro-inflammatory pattern for mouse soluble factors: The fold increases in IL-
10, IL-13, IL-17 and IL-4 concentrations (with respect to the corresponding control group 
mean) for LPS WT and Nbeal2-/- mice were compared (A). Platelet soluble factor assay: The 
fold increases in sCD40L concentration (with respect to the corresponding control group 
mean) for LPS WT and Nbeal2-/- mice were compared (B). Data are presented as means (n = 
6–9). §p < 0.05, §§p < 0.01, and §§§p < 0.001 represent differences between LPS groups. No 
significant difference between Nbeal2-/- groups, between wild type groups, or between PBS 
groups was observed. 
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Figure 2. 
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